Clostridium butyricum Ameliorates the Effect of Coprophagy Prevention on Hepatic Lipid Synthesis in Rabbits via the Gut–Liver Axis

Zhichao Li, Mengjuan Chen, Ran Zhang, Zhitong Wang, Hui He, Zhiyi Wan, Hengjian Li, Hanfang Cai, Zhi Chen, Ming Li, Huifen XuInternational Journal of Molecular Sciences 2023 · DOI

TL;DR

This study investigates how preventing rabbits from eating their own feces (coprophagy prevention, CP) negatively impacts their growth and liver fat metabolism, and how supplementing their diet with Clostridium butyricum can counteract these effects. The findings reveal that C. butyricum restores gut barrier function and rebalances gut microbiota, which in turn improves liver lipid metabolism via the gut-liver axis.

What Problem Does This Paper Address?

Rabbits naturally practice coprophagy, which is essential for nutrient recycling and maintaining gut health. However, preventing this behavior (CP) has been shown to negatively affect growth performance and lead to increased lipid accumulation in the liver. While previous research has hinted at a connection between CP, gut microbiota, and lipid metabolism, the specific mechanisms by which CP disrupts the gut-liver axis and how interventions like probiotic supplementation might help remain unclear. This paper aims to elucidate these mechanisms, focusing on how CP impacts hepatic lipid synthesis and how Clostridium butyricum can mitigate these adverse effects.

Methods

The study employed a multi-faceted approach to investigate the gut-liver axis:

  • Animal Model: New Zealand white rabbits were divided into three groups: control (CON), coprophagy prevention (CP), and CP supplemented with Clostridium butyricum (CPCB).
  • Growth Performance and Meat Quality Analysis: Standard metrics like weight gain, feed efficiency, cooking loss, dripping loss, shear force, and meat color were measured.
  • Serum Biochemistry: Key indicators of liver function and lipid metabolism (ALT, AST, TC, TG, HDL-C, LDL-C) and intestinal permeability (D-LA, iFABP) were analyzed.
  • Cecal Content Analysis:
    • Gene Expression: mRNA levels of tight junction proteins (ZO-1, OCLN, CLDN1) and MUC1 were assessed using qPCR to evaluate gut barrier integrity.
  • Metabolite Analysis: Levels of bile acids (DCA, CDCA, acetic acid, propanoic acid, butyric acid) and GPR43 were quantified.
  • Microbiome Analysis: 16S rRNA gene sequencing was used to characterize the gut microbial community composition (alpha and beta diversity, phyla, genera, and species abundance).
  • Liver Metabolite Analysis:
    • Histology: Oil red O staining was used to visualize and quantify lipid droplet accumulation in liver tissue.
  • Metabolomics: Non-targeted LC-MS/MS was employed to identify differentially accumulated metabolites (DAMs) in the liver. Targeted ELISA was used to quantify specific bile acids (DCA, CDCA).
  • Western Blot: Protein expression levels of key components of the FXR/SHP/SREBP1c pathway were analyzed.
  • Correlation Analysis: Statistical methods were used to explore relationships between gut microbiota composition and measured metabolites.

Datasets

The study utilized samples from rabbits for analysis. 16S rRNA gene sequencing data was deposited in the Sequence Read Archive under project number PRJNA1007274. No new benchmarks were introduced; standard analytical techniques were applied to the collected biological samples.

Key Insights and Ideas

  • CP Disrupts the Gut-Liver Axis: Preventing coprophagy significantly alters the gut microbiome, leading to a decrease in beneficial butyric acid production and compromising the intestinal barrier. This compromised barrier allows increased influx of secondary bile acids (DCA and CDCA) into the liver.
  • C. butyricum as a Gut-Liver Axis Modulator: Supplementation with C. butyricum effectively reverses the negative impacts of CP. It restores gut barrier integrity, rebalances the gut microbiota towards a more beneficial composition, and consequently reduces the harmful bile acid load on the liver.
  • FXR/SHP Pathway is Key: The study highlights the FXR/SHP pathway in the liver as a critical mediator. CP upregulates SHP and FXR, which in turn suppresses SREBP1c and ApoA1, leading to reduced hepatic lipid synthesis. C. butyricum reverses this pathway activation.
  • Microbiota-Metabolite-Host Interaction: The research demonstrates a clear link between specific gut bacteria (e.g., Clostridiales_vadinBB60_group and Christensenellaceae_R-7_group), metabolite levels (butyric acid, DCA, CDCA), and host physiology (gut barrier, liver lipid metabolism).

Key Results

  • Growth Performance: CP significantly reduced average daily gain, final weight, and carcass weight. CPCB supplementation restored these parameters.
  • Meat Quality: CP negatively impacted meat quality (increased cooking loss, dripping loss, shear force; altered color and pH). CPCB supplementation improved these aspects.
  • Intestinal Barrier: CP decreased tight junction protein expression (ZO-1, OCLN, CLDN1) and MUC1 in the cecum. CPCB restored these levels.
  • Bile Acids: CP increased DCA and CDCA in both cecal contents and liver. CPCB significantly reduced these levels in the liver.
  • Liver Lipids: Oil red O staining showed reduced lipid droplet accumulation in the liver of CP rabbits, indicating impaired lipid synthesis. CPCB supplementation restored lipid levels to near control levels.
  • FXR/SHP Pathway: In the liver, CP increased SHP and FXR protein expression while decreasing SREBP1c and ApoA1. CPCB reversed these changes.
  • Microbiota: CP altered the gut microbial composition, decreasing Clostridiales_vadinBB60_group and increasing Christensenellaceae_R-7_group. CPCB reversed these shifts. Clostridiales_vadinBB60_group abundance was positively correlated with butyric acid and negatively with DCA/CDCA.

Limitations and Future Work

The study effectively demonstrates the ameliorating effects of C. butyricum on CP-induced issues via the gut-liver axis. However, the authors do not explicitly detail limitations or suggest specific future research directions beyond the general implication that understanding these mechanisms can inform strategies for improving animal health and productivity. Future work could explore the precise molecular interactions between C. butyricum metabolites and host cells, investigate the long-term effects of supplementation, and potentially explore other probiotic strains or combinations.

Summary updated

Abstract

Coprophagy prevention (CP) affects the growth performance, hepatic lipid synthesis, and gut microbiota in rabbits. Supplementation with <i>Clostridium butyricum</i> (<i>C. butyricum,</i> Strain number: CCTCC M 2019962) has been found to improve growth performance in rabbits. However, it remains unknown whether <i>C. butyricum</i> can ameliorate the effects of CP on hepatic lipid synthesis and the underlying mechanisms are yet to be elucidated. Therefore, this study aimed to investigate the impact of CP on hepatic lipid synthesis and the underlying mechanism based on the gut-liver axis. The findings revealed that supplementation with <i>C. butyricum</i> could reverse CP-related growth performance, lipid accumulation, bile acid synthesis, and inflammation. Furthermore, <i>C. butyricum</i> exerted protective effects on the gut by preserving intestinal barrier integrity and modulating gut microbiota composition; these factors may represent potential mechanisms through which <i>C. butyricum</i> improves CP-related outcomes. Specifically, <i>C. butyricum</i> reshaped the microbiota by increasing butyric acid levels, thereby maintaining secondary bile acid (deoxycholic acid, chenodeoxycholic acid) balance and attenuating the inhibitory effects of the FXR/SHP pathway on lipid synthesis (SREBP1c/ApoA1). Moreover, the activation of butyrate/GPR43pathway by <i>C. butyricum</i> reduced damage to the intestinal barrier (ZO-1/Occludin/Claudin1) and restored the gut immune microenvironment in CP rabbits. In summary, supplementation with <i>C. butyricum</i> can alleviate the adverse effects of CP on growth performance and hepatic lipid synthesis by modulating the gut-liver axis.
BibTeX
@article{li2023clostridium,
  author = {Zhichao Li and Mengjuan Chen and Ran Zhang and Zhitong Wang and Hui He and Zhiyi Wan and Hengjian Li and Hanfang Cai and Zhi Chen and Ming Li and Huifen Xu},
  title = {{Clostridium butyricum Ameliorates the Effect of Coprophagy Prevention on Hepatic Lipid Synthesis in Rabbits via the Gut–Liver Axis}},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms242417554},
}
Figure